Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 7/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119674 | 0.86 | GRM5 (0.47) | MEN1KMT2AGRM5ENPP2ATXN2 | |
| SCHEMBL5119714 | 0.84 | GRM5 (0.45) | MEN1KMT2AGRM5ENPP2ATXN2 | |
| SCHEMBL5129768 | 0.84 | GRM5 (0.54) | GRM5ENPP2ATXN2PKMMGLL | |
| SCHEMBL5125577 | 0.84 | PKM (0.47) | MEN1KMT2AGRM5ENPP2ATXN2 | |
| SCHEMBL5121708 | 0.83 | GRM5 (0.61) | GRM5ENPP2ATXN2 | |
| SCHEMBL5124584 | 0.82 | PKM (0.47) | GRM5ENPP2ATXN2HPGDPKM | |
| SCHEMBL5115972 | 0.82 | PKM (0.64) | MEN1KMT2AGRM5ENPP2ATXN2 | |
| SCHEMBL5122295 | 0.82 | GRM5 (0.43) | GRM5ENPP2ATXN2HPGDPKM | |
| SCHEMBL5118042 | 0.82 | HRH3 (0.49) | GRM5ENPP2ATXN2 | |
| SCHEMBL5115603 | 0.81 | MGLL (0.51) | MEN1KMT2AGRM5ENPP2ATXN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | MEN1 4024/4885KMT2A 1939/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.